anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
SPRIX is not an inhaled product. Do not inhale when administering this product.

Instruct patients to administer as follows:

1\. First hold the finger flange with fingers, and remove the clear plastic cover with opposite hand; then remove the blue plastic safety clip. Keep the clear plastic cover; and throw away the blue plastic safety clip. 

2\. Before using the bottle for the FIRST time, activate the pump. To activate the pump, hold the bottle at arm’s length away from the body with index finger and middle finger resting on the top of the finger flange and thumb supporting the base.

Press down evenly and release the pump 5 times. Patient may not see a spray the first few times he/she presses down. 

The bottle is now ready to use. There is no need to activate the pump again if more doses are used from the bottle.

3\. It’s important to get the medication to the correct place in the nose so it will be most effective. 

\- Blow nose gently to clear nostrils.  
\- Sit up straight or stand. Tilt head slightly forward.  
\- Insert the tip of the container into your right nostril.   
\- Point the container away from the center of your nose.   
\- Hold your breath and spray once into your right nostril, pressing down evenly on both sides.  
\- Immediately after administration, resume breathing through mouth to reduce expelling the product. Also pinch the nose to help retain the spray if it starts to drip.

If only one spray per dose is prescribed, administration is complete; skip to Step 5 below.

4\. If a dose of 2 sprays is prescribed, repeat the process in Step 3 for the left nostril. Again, be sure to point the spray away from the center of nose. Spray once into the left nostril.

5\. Replace the clear plastic cover and place the bottle in a cool, dry location out of direct sunlight, such as inside a medication cabinet. Keep out of reach of children.
The investigators will perform a pilot study of 40 patients who are randomized to either standard of care preparation for an electrophysiology procedure (control arm) vs. Virtual Reality preparation (VR arm). Participants in control arm will have standard preparation for a procedure including discussion of the procedure with the provider the day before the procedure with all questions answered at that time. VR arm participants will have access to the Virtual Reality tour and gear 1 week prior to the procedure. VR arm participants will be instructed to watch the Virtual Reality tour at least three times prior to the procedure but will be encouraged to watch as often as the participants would like. The Virtual Reality equipment will measure how often participants complete the tour. All participants will undergo anxiety measures a total of four times: once at time of recruitment, day of procedure and then 1 week and 4 weeks post procedure. Participants will have cortisol salivary swabs performed 1 week before procedure (before VR use), pre-op visit, day of procedure, and immediately following procedure. Heart rate and blood pressure will be measured on day of procedure.
The Walnut Healthcare Global System Creative tools increase health literacy and reduce healthcare costs by discovering the drivers of spending and spending growth in US healthcare. The system involves multi-talented groups of people and Artificial Intelligence Technology working together to achieve better results by making more precise healthcare decisions. Lifelong educational offerings that develop management competencies and improve professional skills are vital to success through these tools. Increased healthcare use and intensity of services have been the key drivers of healthcare spending growth as the US population continues to age, with healthcare costs rising at all levels. The third eye is also known as self-power to see things through the inner eye in the art and creative environment. It is part of the creative tools called “the subtle body,” which aids the tools to see things through force in the body that moves and sees things through the inner eye.
PROBLEM TO BE SOLVED: To obtain the subject preparation having significantly improved stability of dipivefrin in the vicinity of physiological pH by formulating an aqueous eye drop comprising dipivefrin as an active ingredient with a specific component. SOLUTION: This aqueous eye drop comprises dipivefrin of the formula or its salt as an active ingredient and contains a component selected from an amino acid, benzoic acid and nicotinic acid amide. Glutamic acid, lysine or the like is preferable as the amino acid. In the case of the amino acid, the concentration is preferably 0.1-0.5 (W/V)%. In the case of benzoic acid and nicotinic acid amide, the concentration is preferably 0.5 (W/V)%. The concentration of dipivefrin in the aqueous preparation is preferably 0.04-0.1 (W/V)%. Preferably the aqueous eye drop contains a component selected from a nonionic surfactant, a polyhydric alcohol, a water-soluble polymer and a neutral salt to more improve stability. A polyoxyethylene sorbitan monooleate or the like is preferable as the nonionic surfactant and glycerol or the like is preferable as the polyhydric alcohol.
The present invention discloses siRNA and the application thereof that swine fever virus resistant infects, and belongs to qualification and the Application Areas thereof of swine fever virus resistant siRNA. First the present invention discloses difference target to Pestivirus suis genome N pro , P7, NS5A and NS5B gene swine fever virus resistant infect siRNA, its nucleotide sequence is respectively SEQ? ID? shown in NO.1-12. Does the present invention utilize the restructuring Pestivirus suis of structure to filter out the siRNA that Pestivirus suis interference or inhibit activities is the strongest further, and its nucleotide sequence is respectively SEQ? ID? NO.1, SEQ? ID? NO.7 or SEQ? ID? shown in NO.12. The invention also discloses the expression vector of the siRNA infected containing described swine fever virus resistant and application thereof. The siRNA that swine fever virus resistant of the present invention infects is strong to Pestivirus suis inhibit activities, has the potentiality of medicine or the reagent being prepared into prevention or treatment swine fever.
Following eligibility screening and enrollment, patients will undergo leukapheresis for the collection of peripheral blood mononuclear cells (PBMCs), to enable generation of M28z1XXPD1DNR. Following successful M28z1XXPD1DNR CAR T-cell manufacturing, patients will be reevaluated for eligibility. A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m2 will be administered 2-7 days before the infusion. A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. All patients will be monitored in the hospital for a minimum of 48 h following the administration of CAR T cells.
The invention discloses a clindamycin hydrochloride palmitate capsule and the preparation method. Each capsule contains clindamycin hydrochloride palmitate with a content equal to 35 to 300 milligram of clindamycin hydrochloride. The capsule also contains pharmaceutical excipients such as diluent, disintegrant, solubilizer and seed coating agents. The invention produces granules by dry granulating method, wraps the granules with moisture proof agricultural film, and performs the process of capsule loading. The invention solves the problems of easy moisture absorbing, caking and breaking of capsule shell caused by moisture absorbing. The invention also solves the problems with the product that the formulation is unitary and only granules and dispersible tables are provided, enriches the formulation of the capsule, offers patients with more choices of formulation and the compliance is good. Due to the addition of solubilizer, the clindamycin hydrochloride palmitate is stripped more rapidly and the bioavailability of the invention is enhanced. And the invention adopts the process of moisture proof agricultural film wrapping after dry granulating method, so the activity of the clindamycin hydrochloride palmitate is preserved better, the effect of the drug is better and the drug is much safer; thereby the invention is fit for industrial production.
“Minimalist” antimicrobial peptides are disclosed based on 50 to 80% α,α-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar α,α-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.
Psoriasis is an inflammatory skin disease that affects an estimated 2% to 3% of the world's population. There are a wide range of local and systemic clinical treatments and agents for clearing, or at least reducing the expression of, psoriatic skin lesions. There is a new generation of antipsoriatic drugs that specifically target T-cell mediated inflammatory pathways and that are approved for the treatment of moderate to severe psoriasis in the United States. Alefacept (Amevive) is one of these so-called biologics. Alefacept appears to have several advantages over other systemic antipsoriatic agents and is very well tolerated by patients. Weekly administration of alefacept for 12 weeks reduced the psoriasis area and severity index (PASI) by greater than 75% in 30% of patients. The maximal antipsoriatic effect, however, apparently occurs after the 12-week course has ended. In vitro studies and previous case reports suggested that alefacept's antipsoriatic effect may be augmented when it is administered in combination with UVB. These findings prompted us to conduct a prospective randomized half-body comparison study, in which we ask whether the clinical response of psoriatic lesions to alefacept could be improved by combining alefacept with standard UVB 311nm phototherapy.

Comparison: Psoriatic patients are treated with intravenous alefacept once per week for 12 weeks. One randomized chosen body-half (left or right side) is additionally treated with narrowband UVB (UVB-311nm) three times per week until complete clearance of psoriatic lesions at the UV-treated side. PASI is evaluated before, weekly during, and for 3 to 12 months after alefacept +/- narrowband UVB treatment.
Fluorescent SLN Imaging With Indocyanine Green (ICG), using near-infrared fluorescence imaging, will be used as a dye for SLN mapping. Injections will be performed intraoperative. Concentration of ICG used is 1.25mg/mL, the 25mg dry powder bottle is mixed with 20 mL of sterile water in the operating room, and 4 mL is injected directly into the cervix. This solution was injected intracervically at 3 and 9 o'clock positions, both submucosally and deep into the cervical stroma. A spinal needle 18-gauce is used to inject the ICG. The 4 mL can be divided into 4 separate injections (1 mL each). The ICG should be injected slowly, at a rate of 5 to 10 seconds per quadrant.
BACKGROUND & AIM: Rosacea is a chronic inflammatory, multifactorial disease for which combination therapy could be an effective treatment. In this study, we evaluate the effect of the combination therapy of brimonidine 0.33% and ivermectin 1% as a single cream for the treatment of papulopustular rosacea.
METHOD: A stable and appropriate formulation was prepared by adding the aqueous phase to the lipid phase while being stirred. The stability and physicochemical properties of the formulation were evaluated under accelerated conditions. Twelve patients (36-60 years) with mild to moderate papulopustular rosacea and a Demodex count of five or more were treated with the combination of brimonidine 0.33% and ivermectin 1% cream. Clinician's Erythema Assessment (CEA), Patients Self-Assessment (PSA), skin erythema (ΔE) and lightness (ΔL), and skin biophysical parameters including transepidermal water loss (TEWL), skin hydration, pH, and sebum content, as well as erythema and melanin index and ultrasound parameters, were measured before treatment and 4 and 8 weeks after. Adverse drug reactions were also recorded.
RESULTS: CEA and PSA decreased significantly from 3 to 2 after 8 weeks, respectively (p-value = 0.014 for CEA and 0.010 for PSA). ΔE and ΔL, as well as skin erythema index and TEWL improved after 8 weeks of treatment (p < 0.05). Two patients withdrew from the study in the first week because of local adverse effects; one developed flushing following treatment and left the investigation after 4 weeks and another patient withdrew from the study after 4 weeks due to deciding to become pregnant.
CONCLUSION: Eight-week treatment with the combination of brimonidine 0.33% and ivermectin 1% was shown to be effective for improvement of erythema and inflammatory lesions in mild to moderate papulopustular rosacea.
A method and system of selling healthcare services to a patient. A number of healthcare service providers are contracted and registered with a healthcare marketplace operator (32). Information regarding the healthcare providers is stored in a database (48). A prospective patient is provided with a case statement template having one or more areas to specify clinical and non-clinical requirements of the patient. The patient uses the template to provide case statement information to the marketplace operator. In many instances, the case statement template is completed with the assistance of the patient's primary physician. The case statement information is received and processed by the marketplace operator. The marketplace operator generates a case statement from the case statement information and the case statement is made available or distributed to contracting healthcare providers.
The invention provides a pill for treating hypotension, which is prepared from prepared rehmannia root, astragalus root, red ginseng, cassia, pseudo-ginseng, angelica, small fennel, ass-hide glue, wolfberry fruit, folium artemisiae argyi and licorice. The medicines are ground into fine powder to be refined with honey to obtain the pill. The medicament can be decocted in water for oral dose, can be processed into powder to be brewed, and can be prepared into capsules or medicinal granules. Patients fear cold and are most obvious in autumn and winter, the patients suffer dizziness, limbs of parts of the patients fear cold, and the symptoms are caused by hypotension; and the symptoms belong to qi and blood deficiency and are accompanied with the symptom of relatively low blood pressure caused by yin deficiency of the five internal organs, yang deficiency, blood stagnation, relatively low body temperature and weak myocardial contraction. The angelica, astragalus root, red ginseng and ass-hide glue have the functions of warming and tonifying qi and blood and invigorating vital function; the prepared rehmannia root has the functions of tonifying blood and promoting blood circulation; the pseudo-ginseng has the function of promoting blood circulation to remove blood stasis; the cassia, folium artemisiae argyi and small fennel have the functions of warming the middle-jiao, removing cold, raising the body temperature and enhancing the muscle contraction function; the wolfberry fruit and honey have the functions of tonifying yin and causing laxation; and the licorice has the function of blending all medicines. The pill is unique in prescription, obvious in curative effect, free of any toxic or side effect and stable and safe in medication, and the secret prescription is disclosed at home for the first time.
PURPOSE:To prepare different edible capsules efficiently, by granulating different capsule groups simultaneously in parallel, blending these different capsule groups in a prearranged ratio, followed by carrying out post-treatments successively. CONSTITUTION:A calcium salt or aluminum salt is added to a dissolved viscous agent consisting of a polysaccharide such as guar gum, locust beam gum, etc. It is blended with various kinds of taste drinks such as fruit juice, lactic acid beverage, milk, etc. separately, to prepared different first inner liquids. They are added dropwise to a solution of sodium alginate, etc. to granulate capsules corresponding to each of the taste drinks. These different capsules are collected in a prearranged ratio, sphered, washed with water, and brought into contact with the second inner liquid consisting of the calcium salt or aluminum salt so that the surface is made hard. Granules with good quality are selected, and these mixed capsule groups are bottled or canned.
The invention provides a Salmonella attenuated enteritis rSD strain with the preservation number of CGMCC NO. 13346. The attenuated salmonella enteritidis provided by the invention is used for preparing a recombinant vaccine strain. In another aspect, the present invention provides a recombinant salmonella enteritidis live vector vaccine strain, the genome of which comprises VP2 gene of IBDV. The preservation number of one recombinant salmonella enteritidis live vector vaccine strain is CGMCC NO. 13251. The recombinant vaccine strain constructed by taking the salmonella enteritidis as a host has good genetic stability, and does not generate any mutation in the inserted exogenous gene after continuous passage for 20 generations in a common culture medium; the recombinant bacteria do not contain any resistance, which accords with the development trend of modern bacterial live vaccines, and has good safety without considering antibiotic residues. The recombinant bacteria have good growth and reproduction performance, and the multiplication of the bacteria is not influenced by the insertion of foreign genes.
Samples of nasal mucosa are obtained by mucotomy in general anesthaesia from adult patients with chronic hypertrophic rhinosinusitis. Each tissue sample is divided into 4 parts based on the distance from the nostrils and is dehydrated, thinly sliced and mounted on glass slides. Then the tissue is analyzed with scanning electron microscopy (SEM) and Raman microspectroscopy (RMS) to detect solid particles and characterize the morphology and compositions of the detected particles. A novel method of quantification of distribution of the particles has been designed and used to evaluate interindividual differences in distribution of the particles. History of employment is obtained from the patients and the data are compared with the findings in the tissue samples.

The data acquired from the group of adult patients are compared with the results obtained from a group of control specimen of nasal mucosa harvested from stillborn children. It is presumed that no nano particles will be present in the stillborn children specimen since the mucosa was not exposed to airborne particles.
A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min.
CR-POPF is a multi-center observational prospective cohort study. The research team focuses on whether perioperative abnormal hyperglycemia can independently predict the occurrence of CR-POPF. It is proposed to realize the dynamic monitoring of perioperative blood glucose level by non-invasive continuous glucose monitoring (CGM), and perioperative continuous glucose monitoring can reflect the overall blood glucose trend and mode, which is helpful to further explore the correlation between perioperative abnormal blood glucose level and CR-POPF.

The investigators expect to enroll 600 patients. Based on our previous clinical experience, the incidence of postoperative pancreatic fistula is approximately 20%. We planned to enroll 600 patients during the 6-month enrollment period in three participating hospitals. The sample size would have a statistical power of 81.3% to detect an odds ratio (OR) greater than 1.34 or less than 0.75.

Measurement data consistent with normal distribution were expressed as mean ± standard deviation, and t-test was used for comparison between groups. When not consistent with normal distribution, the measurement data were expressed as quartiles, and the Wilcoxon-Mann-Whitney rank sum test was used for comparison between groups. Count data were expressed as frequency and percentage. Pearson chi-square test or Fisher's exact test was used for comparison between groups. The binary logistic regression method was used to screen the risk factors and stratify the risk levels, P \< 0.05 was considered statistically significant. A generalized estimation equation model was constructed to analyze the correlation between continuous blood glucose monitoring values and postoperative pancreatic fistula. The dependent variable in the model is whether there is pancreatic fistula after operation. The dependent variable in the model was the presence or absence of postoperative pancreatic fistula, and the main variable was the continuous glucose monitoring (CGM) value. The connection function uses the binomial distribution logit function. The multiple measurements of the same patient are set as the group-level variable, and the autocorrelation matrix is selected according to the Quasi-likelihood under Independence Model Criterion (QIC) value of the model. In addition to analysis using generalized estimating equations, continuous glucose monitoring data will be constructed, such as an analysis of the association between pancreatic fistula and the area under the curve for measurement and time beyond normal glucose values. The statistical software was STATA ( version 15.0; stata Corp., Texas, USA ) and R 3.6.1 software ( R Foundation for Statistical Computing, Vienna, Austria ), bilateral P \< 0.05 was considered statistically significant.
Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The drug should NOT be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia).1

Inhibition of fibrinolysis by aminocaproic acid may theoretically result in clotting or thrombosis. However, there is no definite evidence that administration of aminocaproic acid has been responsible for the few reported cases of intravascular clotting which followed this treatment. Rather, it appears that such intravascular clotting was most likely due to the patient's preexisting clinical condition, e.g., the presence of DIC. It has been postulated that extravascular clots formed in vivo may not undergo spontaneous lysis as do normal clots.

Reports have appeared in the literature of an increased incidence of certain neurological deficits such as hydrocephalus, cerebral ischemia, or cerebral vasospasm associated with the use of antifibrinolytic agents in the treatment of subarachnoid hemorrhage (SAH). All of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography. Drug relatedness remains unclear.

Aminocaproic acid should not be administered with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates, as the risk of thrombosis may be increased.
Ten patients will be accrued to stage 1 and treated with standard doses of pembrolizumab, binimetinib and bevacizumab. If the standard doses are not tolerable and 2 or more patients experience a DLT, then patients would be enrolled in dose level -1 which would comprise of standard doses of pembrolizumab and bevacizumab but binimetinib would be at a dose lower of 30 mg PO BID. If 2 or more patients experience a DLT at dose level -1, then patients will be enrolled in dose level -2 which will comprise of standard doses of pembrolizumab and bevacizumab but a lower dose of binimetinib at 15 mg BID. Upon determination of the safety and tolerability of the treatment regimen, the study will proceed to stage 2.